<DOC>
	<DOC>NCT00460408</DOC>
	<brief_summary>The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtaining additional safety information when Macugen is used in real world settings by practitioners in Europe treating patients with neovascular (wet) age-related macular degeneration (AMD). The study will provide information about physician practice patterns and characteristics of patients treated with Macugen.</brief_summary>
	<brief_title>Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration</brief_title>
	<detailed_description>No comparator Patients with age-related macular degeneration</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Neovascular AMD patients who are eligible for Macugen therapy based on the approved label Active or suspected ocular or periocular infection. Known hypersensitivity to the active substance or any of its excipients.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Macular degeneration</keyword>
	<keyword>Safety</keyword>
	<keyword>Non-interventional</keyword>
	<keyword>Non-randomized</keyword>
</DOC>